Stock A234080 JW LIFESCIENCE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials JW Lifescience Corporation

Equities

A234080

KR7234080000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 17/05/2024 am IST 		5-day change 1st Jan Change
12,450 KRW +0.48% Intraday chart for JW Lifescience Corporation -0.40% -3.26%
2023 JW Lifescience Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 JW Lifescience Corporation(KOSE:A234080) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,47,568 3,13,524 3,28,567 2,14,461 1,88,137 1,99,286
Enterprise Value (EV) 1 3,89,821 3,48,370 3,62,512 2,55,871 2,26,460 2,17,251
P/E ratio 22 x 14.3 x 19 x 16.7 x 12.6 x 7.08 x
Yield 2.28% 2.53% 2.41% 3.61% 4.12% 3.89%
Capitalization / Revenue 2.24 x 1.84 x 1.79 x 1.26 x 1 x 0.96 x
EV / Revenue 2.51 x 2.05 x 1.98 x 1.51 x 1.2 x 1.05 x
EV / EBITDA 11.3 x 8.42 x 7.01 x 6.14 x 5.39 x 4.68 x
EV / FCF 17.3 x 23.2 x 16.6 x 24.9 x 26 x 8.11 x
FCF Yield 5.79% 4.32% 6.01% 4.01% 3.85% 12.3%
Price to Book 3.18 x 2.56 x 2.48 x 1.63 x 1.34 x 1.25 x
Nbr of stocks (in thousands) 15,835 15,835 15,835 15,485 15,485 15,485
Reference price 2 21,950 19,800 20,750 13,850 12,150 12,870
Announcement Date 21/03/19 19/03/20 25/03/21 28/03/22 21/03/23 14/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,55,230 1,70,221 1,83,521 1,69,817 1,88,931 2,06,860
EBITDA 1 34,640 41,375 51,697 41,661 42,045 46,393
EBIT 1 23,541 29,749 39,451 28,417 27,089 30,862
Operating Margin 15.17% 17.48% 21.5% 16.73% 14.34% 14.92%
Earnings before Tax (EBT) 1 21,311 28,331 22,740 18,287 20,782 33,708
Net income 1 15,821 21,938 17,300 12,914 14,961 28,144
Net margin 10.19% 12.89% 9.43% 7.6% 7.92% 13.61%
EPS 2 999.1 1,385 1,093 828.8 966.0 1,818
Free Cash Flow 1 22,573 15,043 21,798 10,273 8,717 26,784
FCF margin 14.54% 8.84% 11.88% 6.05% 4.61% 12.95%
FCF Conversion (EBITDA) 65.17% 36.36% 42.16% 24.66% 20.73% 57.73%
FCF Conversion (Net income) 142.68% 68.57% 126% 79.55% 58.26% 95.17%
Dividend per Share 2 500.0 500.0 500.0 500.0 500.0 500.0
Announcement Date 21/03/19 19/03/20 25/03/21 28/03/22 21/03/23 14/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 42,253 34,846 33,945 41,410 38,322 17,965
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.22 x 0.8422 x 0.6566 x 0.994 x 0.9115 x 0.3872 x
Free Cash Flow 1 22,573 15,043 21,798 10,273 8,717 26,784
ROE (net income / shareholders' equity) 15% 18.9% 13.6% 9.78% 11% 18.8%
ROA (Net income/ Total Assets) 7.37% 9.24% 11.9% 8.19% 7.17% 7.58%
Assets 1 2,14,731 2,37,321 1,45,874 1,57,733 2,08,729 3,71,180
Book Value Per Share 2 6,900 7,744 8,367 8,492 9,063 10,294
Cash Flow per Share 2 807.0 623.0 164.0 318.0 253.0 1,306
Capex 1 10,042 8,092 15,931 18,976 8,079 8,153
Capex / Sales 6.47% 4.75% 8.68% 11.17% 4.28% 3.94%
Announcement Date 21/03/19 19/03/20 25/03/21 28/03/22 21/03/23 14/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JW LIFESCIENCE CORPORATION Stock JW Lifescience Corporation
-3.26% 142M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 693B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 584B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 372B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 211B
NOVARTIS AG Stock Novartis AG
+10.02% 210B
AMGEN INC. Stock Amgen Inc.
+8.49% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A234080 Stock
  4. Financials JW Lifescience Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW